Nkarta, Inc. — Biomedical Watch V2

Traitements3programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
NKX019Primary objective: Safety and tolerability of NKX019, administered after lymphodepletion (LD). Secondary objectives: * Assess clinical activity of NKX019 in subjects with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN) * Characterize pharmacokinetics (PK) of NKX019 * Characterize immunogenicity of NKX019	Lupus, Myopathies	Phase 1/2	À vérifier	United States, Australia, Puerto Rico	À vérifier
NKX019Primary objective: Safety and tolerability of NKX019, administered after lymphodepletion (LD). Secondary objectives: * Assess clinical activity of NKX019 in subjects with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN) * Characterize pharmacokinetics (PK) of NKX019 * Characterize immunogenicity of NKX019	Lupus	Phase 1	Thérapie cellulaire	United States	À vérifier
NKX019Primary objective: Safety and tolerability of NKX019, administered after lymphodepletion (LD). Secondary objectives: * Assess clinical activity of NKX019 in subjects with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN) * Characterize pharmacokinetics (PK) of NKX019 * Characterize immunogenicity of NKX019	Myopathies	Phase 1/2		United States, Australia, Puerto Rico	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
NKX019	Myopathies	Phase 1/2	NCT06733935	A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)	RECRUITING
NKX019	Lupus	Phase 1	NCT06518668	A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus	ENROLLING_BY_INVITATION

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.